查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1462644

到 2030 年免疫腫瘤檢測市場預測：按產品、適應症、技術、應用和地區進行的全球分析

Immuno Oncology Assay Market Forecasts to 2030 - Global Analysis By Product, Indication, Technology, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球免疫腫瘤檢測市場規模為 50.4 億美元，預計在預測期內年複合成長率為 12.8%，到 2030 年將達到 117.1 億美元。

免疫腫瘤學檢測市場是指醫療保健行業內的一個部門，專注於利用人體免疫系統支持癌症研究和治療的檢測方法的開發和商業化。這些檢測方法在藥物開發中發揮重要作用，能夠評估新型免疫腫瘤治療方法，幫助研究人員識別有前景的候選藥物並評估其療效和安全性。

根據 ECIS 的數據，2040 年歐洲癌症患者人數預計將達到 336 萬人，而 2025 年將達到 294 萬人。

人們對免疫療法的興趣日益濃厚

免疫療法已成為一種有前途的癌症治療方法，它利用人體的免疫系統有效對抗腫瘤。傳統的癌症治療經常遇到抗藥性，並可能產生嚴重的副作用，因此免疫療法很有吸引力，因為它的副作用較少，並且有望產生有針對性的持久反應。免疫腫瘤學檢測對於免疫療法藥物的開發和評估至關重要，使研究人員和臨床醫生能夠評估其療效、安全性和作用機制。

開發成本高

免疫腫瘤學檢測法的研發過程包括廣泛的驗證研究、檢測法通訊協定最佳化和臨床驗證研究，以確保準確性、重現性和法律規章。此類活動需要大量的財務投資，包括設備、試劑、人員和監管備案。對於資源有限的小型企業來說，高昂的初始成本和漫長的開發時間可能會阻礙它們進入市場並與較大的現有企業進行有效競爭。

技術進步

多重檢測、次世代定序(NGS) 和高通量篩檢等技術創新使研究人員能夠以更高的效率和精度同時分析多個參數，從而徹底改變了免疫腫瘤學領域。多重檢測可測量單一樣本中的多種分析物，從而全面了解免疫系統與癌細胞之間複雜的相互作用。 NGS 技術為基因組和轉錄組分析提供了前所未有的機會，有助於識別新型生物標記和治療標靶。

來自替代技術的競爭

液態切片和診斷成像方法等替代技術具有非侵入性、即時監測和全面分子分析等獨特優勢。這些替代技術有可能為癌症進展、治療效果和患者結果提供有價值的見解，並且在許多情況下補充甚至超越免疫腫瘤學測試的能力。因此，研究人員和臨床醫生可能會選擇這些替代方法，特別是在免疫腫瘤學檢測受到樣本可用性、檢測複雜性或成本限制的情況下。

COVID-19 的影響：

最初，疫情爆發擾亂了供應鏈、實驗室業務和臨床試驗，導致檢測開發、驗證和商業化延遲。對非必要醫療程序和實驗室活動的限制也阻礙了免疫腫瘤學研究的實施以及檢測技術在臨床實踐中的採用。此外，醫療保健資源和資金被用於對抗 COVID-19，從而轉移了對免疫腫瘤學研究和開發的注意力和投資。然而，隨著大流行的進展，免疫學和感染疾病研究的重要性被認知，可能引發對免疫腫瘤學檢測的興趣和投資。

預計消耗品領域在預測期內將是最大的

在預測期內，消耗品領域佔據了市場的最大佔有率，因為它在支持免疫腫瘤檢測的操作和擴充性發揮著至關重要的作用。在癌症發生率上升和免疫療法普及的推動下，對免疫腫瘤檢測的需求持續成長，對耗材的需求也相應成長。此外，檢測開發的創新通常依賴於旨在提高檢測靈敏度、特異性和通量的專用耗材。這創造了免疫腫瘤檢測市場對耗材的持續需求。

流式細胞技術領域預計在預測期內年複合成長率最高

由於流式細胞技術儀在分析免疫細胞群及其在腫瘤微環境中的相互作用方面的多功能性和精確性，預計在預測期內將出現最高的年複合成長率。在單細胞層面同時測量多個參數的能力為了解免疫細胞表現型、活化狀態和功能反應提供了寶貴的見解。此外，流式細胞技術可以評估免疫查核點表達和細胞激素的產生，有助於評估免疫治療效果和患者分層。

佔比最高的地區

在估計期間，亞太地區佔據最大佔有率。隨著人口快速成長、人口老化和生活方式的改變，亞太國家的癌症發病率和死亡率正在迅速上升。都市化、菸草消費、污染和飲食習慣等因素導致該地區癌症發生率增加。因此，醫療基礎設施的改善、診斷服務的獲取以及對癌症篩檢計劃的認知的提高正在導致癌症患者的早期發現和診斷。

年複合成長率最高的地區：

預計歐洲地區在預測期內將實現盈利成長。歐洲藥品管理局 (EMA) 和歐盟委員會等歐洲監管機構建立的嚴格法規結構確保了臨床研究和患者治療中使用的免疫腫瘤檢測的安全性、有效性和品質。歐洲法規環境強調透明度、基於證據的決策和道德考慮，這有助於在相關人員之間建立對免疫腫瘤學檢測的信任和信心。因此，監管合規性將透過促進及時進入市場、促進創新以及加速在整個歐洲採用精準醫學和個人化癌症治療的免疫腫瘤學測試來推動市場成長。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次研究資料
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球免疫腫瘤檢測市場：依產品

  • 軟體
  • 消耗品
  • 裝置
  • 其他產品

第6章全球免疫腫瘤檢測市場：依適應症分類

  • 膀胱癌
  • 黑色素瘤癌症
  • 肺癌
  • 大腸直腸癌
  • 乳癌
  • 淋巴瘤
  • 其他適應症

第7章全球免疫腫瘤檢測市場：依技術分類

  • 聚合酵素鏈鎖反應(PCR)
  • 免疫學測試
  • 流式細胞技術
  • 次世代定序（NGS）
  • 原位雜合技術
  • 其他技術

第8章全球免疫腫瘤檢測市場：依應用分類

  • 臨床診斷
  • 研究用途
  • 其他用途

第9章全球免疫腫瘤檢測市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Agilent Technologies, Inc
  • Bio-Rad Laboratories, Inc
  • Charles River Laboratories, Inc
  • F. Hoffmann-La Roche Ltd
  • Guardant Health, Inc
  • HTG Molecular Diagnostics, Inc
  • llumina, Inc
  • NanoString Technologies, Inc
  • Novartis International AG
  • Perkinelmer, Inc
  • Qiagen Nv
  • Sartorius AG
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc
Product Code: SMRC25695

According to Stratistics MRC, the Global Immuno Oncology Assay Market is accounted for $5.04 billion in 2023 and is expected to reach $11.71 billion by 2030 growing at a CAGR of 12.8% during the forecast period. The Immuno Oncology Assay Market refers to the sector within the healthcare industry focused on developing and commercializing assays that aid in the study and treatment of cancer by harnessing the body's immune system. These assays play a pivotal role in drug development by enabling the evaluation of novel immuno-oncology therapies, helping researchers identify promising candidates and assess their efficacy and safety profiles.

According to the ECIS, the European cancer burden is expected to reach 3.36 million new cases by 2040, compared to 2.94 million patients in 2025.

Market Dynamics:

Driver:

Growing interest in immunotherapy

Immunotherapy has emerged as a promising approach for cancer treatment, leveraging the body's immune system to combat tumors effectively. As traditional cancer treatments often encounter resistance and can have severe side effects, the appeal of immunotherapy lies in its potential for targeted and durable responses with fewer adverse effects. Immuno-oncology assays are integral to the development and evaluation of immunotherapeutic agents, allowing researchers and clinicians to assess their efficacy, safety, and mechanism of action.

Restraint:

High development costs

The research and development (R&D) process for immuno-oncology assays involves extensive validation studies, optimization of assay protocols, and clinical validation trials to ensure accuracy, reproducibility, and regulatory compliance. These activities require substantial financial investment, including expenditures on equipment, reagents, personnel, and regulatory submissions. For smaller companies with limited resources, the high upfront costs and long development timelines can be prohibitive, preventing them from entering the market or competing effectively with larger established players.

Opportunity:

Technological advancements

Innovations such as multiplex assays, next-generation sequencing (NGS), and high-throughput screening are revolutionizing the field of immuno-oncology by enabling researchers to analyze multiple parameters simultaneously with greater efficiency and precision. Multiplex assays allow the measurement of multiple analytes in a single sample, providing comprehensive insights into the complex interactions between the immune system and cancer cells. NGS technologies offer unprecedented opportunities for genomic and transcriptomic profiling, facilitating the identification of novel biomarkers and therapeutic targets.

Threat:

Competition from alternative technologies

Alternative technologies such as liquid biopsy assays or imaging modalities offer distinct advantages, such as non-invasiveness, real-time monitoring, and comprehensive molecular profiling. These alternatives may provide valuable insights into cancer progression, treatment response, and patient outcomes, often in ways that complement or surpass the capabilities of immuno-oncology assays. As a result, researchers and clinicians may opt for these alternative approaches, particularly in settings where immuno-oncology assays may be limited by sample availability, assay complexity, or cost.

Covid-19 Impact:

Initially, the outbreak led to disruptions in supply chains, laboratory operations, and clinical trials, causing delays in assay development, validation, and commercialization. Restrictions on non-essential medical procedures and laboratory activities also hindered the conduct of immuno-oncology research and the adoption of assay technologies in clinical settings. Furthermore, the redirection of healthcare resources and funding towards COVID-19 response efforts diverted attention and investment away from immuno-oncology research and development. However, as the pandemic progressed, there emerged a heightened recognition of the importance of immunology and infectious disease research, potentially stimulating interest and investment in immuno-oncology assays.

The consumables segment is expected to be the largest during the forecast period

Consumables segment dominated the largest share of the market during the forecast period due to its indispensable role in supporting the operation and scalability of immuno-oncology assays. As the demand for immuno-oncology assays continues to rise, fueled by increasing cancer prevalence and the growing adoption of immunotherapy, the need for consumables also escalates proportionally. Moreover, innovations in assay development often rely on specialized consumables designed to improve assay sensitivity, specificity, and throughput. This creates a continuous demand for consumables within the immuno-oncology assay market.

The flow cytometry segment is expected to have the highest CAGR during the forecast period

Flow Cytometry segment is expected to have the highest CAGR during the projection period due to its versatility and precision in analyzing immune cell populations and their interactions within the tumor microenvironment. This segment allows for the simultaneous measurement of multiple parameters at the single-cell level, providing valuable insights into immune cell phenotypes, activation states, and functional responses. Additionally, flow cytometry enables the assessment of immune checkpoint expression and cytokine production, facilitating the evaluation of immunotherapy efficacy and patient stratification.

Region with largest share:

Asia Pacific region commanded the largest share over the extrapolated period. With a rapidly expanding population, aging demographics, and changing lifestyles, countries across Asia Pacific are experiencing a surge in cancer incidence and mortality rates. Factors such as urbanization, tobacco consumption, pollution, and dietary habits contribute to the rising burden of cancer in the region. As a result, improvements in healthcare infrastructure, access to diagnostic services, and awareness of cancer screening programs are leading to earlier detection and diagnosis of cancer cases in the region thereby enhancing the market growth.

Region with highest CAGR:

Europe region is poised to witness profitable growth throughout the estimation period. The stringent regulatory framework established by European regulatory bodies, such as the European Medicines Agency (EMA) and the European Commission, ensures the safety, efficacy, and quality of immuno-oncology assays used in clinical research and patient care. The European regulatory environment emphasizes transparency, evidence-based decision-making, and ethical considerations, which contribute to building trust and confidence in immuno-oncology assays among stakeholders. As a result, regulatory compliance serves as a catalyst for market growth by facilitating timely market entry, encouraging innovation, and promoting the adoption of immuno-oncology assays for precision medicine and personalized cancer care throughout the European region.

Key players in the market

Some of the key players in Immuno Oncology Assay market include Agilent Technologies, Inc, Bio-Rad Laboratories, Inc, Charles River Laboratories, Inc, F. Hoffmann-La Roche Ltd, Guardant Health, Inc, HTG Molecular Diagnostics, Inc, llumina, Inc, NanoString Technologies, Inc, Novartis International AG, Perkinelmer, Inc, Qiagen Nv, Sartorius AG, Sysmex Corporation and Thermo Fisher Scientific, Inc.

Key Developments:

In January 2024, Thermo Fisher Scientific introduced Gibco(TM) Cell Therapy Systems (CTS(TM)) Cellmation(TM) Software, a new automation solution. It integrates workflows across Thermo Fisher Scientific cell therapy instruments and ensures cGMP compliance for innovators in breakthrough cell therapies.

In March 2023, Mimetas, a company that models human diseases, formed a strategic alliance with Astellas Pharma Inc., a multinational pharmaceutical corporation. The partnership entails using MIMETAS' exhaustive tumor models to assist the next generation of immuno-oncological therapies.

In February 2023, Agilent Technologies, Inc. revealed that their xCELLigence RTCA HT (real-time cell analysis high-throughput) platform is compatible with the BioTek BioSpa 8 Automated Incubator. This combination, developed in response to market demands, enables a higher level of workflow automation and provides novel functionality for developing label-free high-throughput potency assays for the immuno-oncology market and high-throughput viral cytopathic effects (CPE) assays for the vaccine market.

Products Covered:

  • Software
  • Consumables
  • Instruments
  • Other Products

Indications Covered:

  • Bladder Cancer
  • Melanoma Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Lymphoma
  • Other Indications

Technologies Covered:

  • Polymerase Chain Reaction (PCR)
  • Immunoassays
  • Flow Cytometry
  • Next-generation Sequencing (NGS)
  • In Situ Hybridization
  • Other Technologies

Applications Covered:

  • Clinical Diagnostics
  • Research Applications
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Immuno Oncology Assay Market, By Product

  • 5.1 Introduction
  • 5.2 Software
  • 5.3 Consumables
  • 5.4 Instruments
  • 5.5 Other Products

6 Global Immuno Oncology Assay Market, By Indication

  • 6.1 Introduction
  • 6.2 Bladder Cancer
  • 6.3 Melanoma Cancer
  • 6.4 Lung Cancer
  • 6.5 Colorectal Cancer
  • 6.6 Breast Cancer
  • 6.7 Lymphoma
  • 6.8 Other Indications

7 Global Immuno Oncology Assay Market, By Technology

  • 7.1 Introduction
  • 7.2 Polymerase Chain Reaction (PCR)
  • 7.3 Immunoassays
  • 7.4 Flow Cytometry
  • 7.5 Next-generation Sequencing (NGS)
  • 7.6 In Situ Hybridization
  • 7.7 Other Technologies

8 Global Immuno Oncology Assay Market, By Application

  • 8.1 Introduction
  • 8.2 Clinical Diagnostics
  • 8.3 Research Applications
  • 8.4 Other Applications

9 Global Immuno Oncology Assay Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Agilent Technologies, Inc
  • 11.2 Bio-Rad Laboratories, Inc
  • 11.3 Charles River Laboratories, Inc
  • 11.4 F. Hoffmann-La Roche Ltd
  • 11.5 Guardant Health, Inc
  • 11.6 HTG Molecular Diagnostics, Inc
  • 11.7 llumina, Inc
  • 11.8 NanoString Technologies, Inc
  • 11.9 Novartis International AG
  • 11.10 Perkinelmer, Inc
  • 11.11 Qiagen Nv
  • 11.12 Sartorius AG
  • 11.13 Sysmex Corporation
  • 11.14 Thermo Fisher Scientific, Inc

List of Tables

  • Table 1 Global Immuno Oncology Assay Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Immuno Oncology Assay Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Immuno Oncology Assay Market Outlook, By Software (2021-2030) ($MN)
  • Table 4 Global Immuno Oncology Assay Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 5 Global Immuno Oncology Assay Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 6 Global Immuno Oncology Assay Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 7 Global Immuno Oncology Assay Market Outlook, By Indication (2021-2030) ($MN)
  • Table 8 Global Immuno Oncology Assay Market Outlook, By Bladder Cancer (2021-2030) ($MN)
  • Table 9 Global Immuno Oncology Assay Market Outlook, By Melanoma Cancer (2021-2030) ($MN)
  • Table 10 Global Immuno Oncology Assay Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 11 Global Immuno Oncology Assay Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 12 Global Immuno Oncology Assay Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 13 Global Immuno Oncology Assay Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 14 Global Immuno Oncology Assay Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 15 Global Immuno Oncology Assay Market Outlook, By Technology (2021-2030) ($MN)
  • Table 16 Global Immuno Oncology Assay Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 17 Global Immuno Oncology Assay Market Outlook, By Immunoassays (2021-2030) ($MN)
  • Table 18 Global Immuno Oncology Assay Market Outlook, By Flow Cytometry (2021-2030) ($MN)
  • Table 19 Global Immuno Oncology Assay Market Outlook, By Next-generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 20 Global Immuno Oncology Assay Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 21 Global Immuno Oncology Assay Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 22 Global Immuno Oncology Assay Market Outlook, By Application (2021-2030) ($MN)
  • Table 23 Global Immuno Oncology Assay Market Outlook, By Clinical Diagnostics (2021-2030) ($MN)
  • Table 24 Global Immuno Oncology Assay Market Outlook, By Research Applications (2021-2030) ($MN)
  • Table 25 Global Immuno Oncology Assay Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 26 North America Immuno Oncology Assay Market Outlook, By Country (2021-2030) ($MN)
  • Table 27 North America Immuno Oncology Assay Market Outlook, By Product (2021-2030) ($MN)
  • Table 28 North America Immuno Oncology Assay Market Outlook, By Software (2021-2030) ($MN)
  • Table 29 North America Immuno Oncology Assay Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 30 North America Immuno Oncology Assay Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 31 North America Immuno Oncology Assay Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 32 North America Immuno Oncology Assay Market Outlook, By Indication (2021-2030) ($MN)
  • Table 33 North America Immuno Oncology Assay Market Outlook, By Bladder Cancer (2021-2030) ($MN)
  • Table 34 North America Immuno Oncology Assay Market Outlook, By Melanoma Cancer (2021-2030) ($MN)
  • Table 35 North America Immuno Oncology Assay Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 36 North America Immuno Oncology Assay Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 37 North America Immuno Oncology Assay Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 38 North America Immuno Oncology Assay Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 39 North America Immuno Oncology Assay Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 40 North America Immuno Oncology Assay Market Outlook, By Technology (2021-2030) ($MN)
  • Table 41 North America Immuno Oncology Assay Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 42 North America Immuno Oncology Assay Market Outlook, By Immunoassays (2021-2030) ($MN)
  • Table 43 North America Immuno Oncology Assay Market Outlook, By Flow Cytometry (2021-2030) ($MN)
  • Table 44 North America Immuno Oncology Assay Market Outlook, By Next-generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 45 North America Immuno Oncology Assay Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 46 North America Immuno Oncology Assay Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 47 North America Immuno Oncology Assay Market Outlook, By Application (2021-2030) ($MN)
  • Table 48 North America Immuno Oncology Assay Market Outlook, By Clinical Diagnostics (2021-2030) ($MN)
  • Table 49 North America Immuno Oncology Assay Market Outlook, By Research Applications (2021-2030) ($MN)
  • Table 50 North America Immuno Oncology Assay Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 51 Europe Immuno Oncology Assay Market Outlook, By Country (2021-2030) ($MN)
  • Table 52 Europe Immuno Oncology Assay Market Outlook, By Product (2021-2030) ($MN)
  • Table 53 Europe Immuno Oncology Assay Market Outlook, By Software (2021-2030) ($MN)
  • Table 54 Europe Immuno Oncology Assay Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 55 Europe Immuno Oncology Assay Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 56 Europe Immuno Oncology Assay Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 57 Europe Immuno Oncology Assay Market Outlook, By Indication (2021-2030) ($MN)
  • Table 58 Europe Immuno Oncology Assay Market Outlook, By Bladder Cancer (2021-2030) ($MN)
  • Table 59 Europe Immuno Oncology Assay Market Outlook, By Melanoma Cancer (2021-2030) ($MN)
  • Table 60 Europe Immuno Oncology Assay Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 61 Europe Immuno Oncology Assay Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 62 Europe Immuno Oncology Assay Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 63 Europe Immuno Oncology Assay Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 64 Europe Immuno Oncology Assay Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 65 Europe Immuno Oncology Assay Market Outlook, By Technology (2021-2030) ($MN)
  • Table 66 Europe Immuno Oncology Assay Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 67 Europe Immuno Oncology Assay Market Outlook, By Immunoassays (2021-2030) ($MN)
  • Table 68 Europe Immuno Oncology Assay Market Outlook, By Flow Cytometry (2021-2030) ($MN)
  • Table 69 Europe Immuno Oncology Assay Market Outlook, By Next-generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 70 Europe Immuno Oncology Assay Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 71 Europe Immuno Oncology Assay Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 72 Europe Immuno Oncology Assay Market Outlook, By Application (2021-2030) ($MN)
  • Table 73 Europe Immuno Oncology Assay Market Outlook, By Clinical Diagnostics (2021-2030) ($MN)
  • Table 74 Europe Immuno Oncology Assay Market Outlook, By Research Applications (2021-2030) ($MN)
  • Table 75 Europe Immuno Oncology Assay Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 76 Asia Pacific Immuno Oncology Assay Market Outlook, By Country (2021-2030) ($MN)
  • Table 77 Asia Pacific Immuno Oncology Assay Market Outlook, By Product (2021-2030) ($MN)
  • Table 78 Asia Pacific Immuno Oncology Assay Market Outlook, By Software (2021-2030) ($MN)
  • Table 79 Asia Pacific Immuno Oncology Assay Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 80 Asia Pacific Immuno Oncology Assay Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 81 Asia Pacific Immuno Oncology Assay Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 82 Asia Pacific Immuno Oncology Assay Market Outlook, By Indication (2021-2030) ($MN)
  • Table 83 Asia Pacific Immuno Oncology Assay Market Outlook, By Bladder Cancer (2021-2030) ($MN)
  • Table 84 Asia Pacific Immuno Oncology Assay Market Outlook, By Melanoma Cancer (2021-2030) ($MN)
  • Table 85 Asia Pacific Immuno Oncology Assay Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 86 Asia Pacific Immuno Oncology Assay Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 87 Asia Pacific Immuno Oncology Assay Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 88 Asia Pacific Immuno Oncology Assay Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 89 Asia Pacific Immuno Oncology Assay Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 90 Asia Pacific Immuno Oncology Assay Market Outlook, By Technology (2021-2030) ($MN)
  • Table 91 Asia Pacific Immuno Oncology Assay Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 92 Asia Pacific Immuno Oncology Assay Market Outlook, By Immunoassays (2021-2030) ($MN)
  • Table 93 Asia Pacific Immuno Oncology Assay Market Outlook, By Flow Cytometry (2021-2030) ($MN)
  • Table 94 Asia Pacific Immuno Oncology Assay Market Outlook, By Next-generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 95 Asia Pacific Immuno Oncology Assay Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 96 Asia Pacific Immuno Oncology Assay Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 97 Asia Pacific Immuno Oncology Assay Market Outlook, By Application (2021-2030) ($MN)
  • Table 98 Asia Pacific Immuno Oncology Assay Market Outlook, By Clinical Diagnostics (2021-2030) ($MN)
  • Table 99 Asia Pacific Immuno Oncology Assay Market Outlook, By Research Applications (2021-2030) ($MN)
  • Table 100 Asia Pacific Immuno Oncology Assay Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 101 South America Immuno Oncology Assay Market Outlook, By Country (2021-2030) ($MN)
  • Table 102 South America Immuno Oncology Assay Market Outlook, By Product (2021-2030) ($MN)
  • Table 103 South America Immuno Oncology Assay Market Outlook, By Software (2021-2030) ($MN)
  • Table 104 South America Immuno Oncology Assay Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 105 South America Immuno Oncology Assay Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 106 South America Immuno Oncology Assay Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 107 South America Immuno Oncology Assay Market Outlook, By Indication (2021-2030) ($MN)
  • Table 108 South America Immuno Oncology Assay Market Outlook, By Bladder Cancer (2021-2030) ($MN)
  • Table 109 South America Immuno Oncology Assay Market Outlook, By Melanoma Cancer (2021-2030) ($MN)
  • Table 110 South America Immuno Oncology Assay Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 111 South America Immuno Oncology Assay Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 112 South America Immuno Oncology Assay Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 113 South America Immuno Oncology Assay Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 114 South America Immuno Oncology Assay Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 115 South America Immuno Oncology Assay Market Outlook, By Technology (2021-2030) ($MN)
  • Table 116 South America Immuno Oncology Assay Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 117 South America Immuno Oncology Assay Market Outlook, By Immunoassays (2021-2030) ($MN)
  • Table 118 South America Immuno Oncology Assay Market Outlook, By Flow Cytometry (2021-2030) ($MN)
  • Table 119 South America Immuno Oncology Assay Market Outlook, By Next-generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 120 South America Immuno Oncology Assay Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 121 South America Immuno Oncology Assay Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 122 South America Immuno Oncology Assay Market Outlook, By Application (2021-2030) ($MN)
  • Table 123 South America Immuno Oncology Assay Market Outlook, By Clinical Diagnostics (2021-2030) ($MN)
  • Table 124 South America Immuno Oncology Assay Market Outlook, By Research Applications (2021-2030) ($MN)
  • Table 125 South America Immuno Oncology Assay Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 126 Middle East & Africa Immuno Oncology Assay Market Outlook, By Country (2021-2030) ($MN)
  • Table 127 Middle East & Africa Immuno Oncology Assay Market Outlook, By Product (2021-2030) ($MN)
  • Table 128 Middle East & Africa Immuno Oncology Assay Market Outlook, By Software (2021-2030) ($MN)
  • Table 129 Middle East & Africa Immuno Oncology Assay Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 130 Middle East & Africa Immuno Oncology Assay Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 131 Middle East & Africa Immuno Oncology Assay Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 132 Middle East & Africa Immuno Oncology Assay Market Outlook, By Indication (2021-2030) ($MN)
  • Table 133 Middle East & Africa Immuno Oncology Assay Market Outlook, By Bladder Cancer (2021-2030) ($MN)
  • Table 134 Middle East & Africa Immuno Oncology Assay Market Outlook, By Melanoma Cancer (2021-2030) ($MN)
  • Table 135 Middle East & Africa Immuno Oncology Assay Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 136 Middle East & Africa Immuno Oncology Assay Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 137 Middle East & Africa Immuno Oncology Assay Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 138 Middle East & Africa Immuno Oncology Assay Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 139 Middle East & Africa Immuno Oncology Assay Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 140 Middle East & Africa Immuno Oncology Assay Market Outlook, By Technology (2021-2030) ($MN)
  • Table 141 Middle East & Africa Immuno Oncology Assay Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 142 Middle East & Africa Immuno Oncology Assay Market Outlook, By Immunoassays (2021-2030) ($MN)
  • Table 143 Middle East & Africa Immuno Oncology Assay Market Outlook, By Flow Cytometry (2021-2030) ($MN)
  • Table 144 Middle East & Africa Immuno Oncology Assay Market Outlook, By Next-generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 145 Middle East & Africa Immuno Oncology Assay Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 146 Middle East & Africa Immuno Oncology Assay Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 147 Middle East & Africa Immuno Oncology Assay Market Outlook, By Application (2021-2030) ($MN)
  • Table 148 Middle East & Africa Immuno Oncology Assay Market Outlook, By Clinical Diagnostics (2021-2030) ($MN)
  • Table 149 Middle East & Africa Immuno Oncology Assay Market Outlook, By Research Applications (2021-2030) ($MN)
  • Table 150 Middle East & Africa Immuno Oncology Assay Market Outlook, By Other Applications (2021-2030) ($MN)